Entera Bio Ltd.
ENTX | NASDAQ
$2.98
+$0.02 (+0.68%)
Sep 22, 2026, 2:15 PM ET · Market open
Company Profile
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
Key Executives
| Name | Position |
|---|---|
| Miranda J. Toledano | Chief Executive Officer & Director |
| Dana Yaacov-Garbeli | Chief Financial Officer |
| Hillel Galitzer | Chief Operating Officer |
| Cherin Smith | Executive Vice President & Head of Clinical Operations |
| Constantin Itin | Head of Biopharmaceutics & Bioanalytics |
| Gregory Burshtein | Chief of Research & Development |
| Michele McDermott | MD & EVP of Medical Affairs |
| Rachel Wagman | Chief Clinical Advisor |
| Riccardo Paolo Camisasca | Chief Medical Officer |
Entera Bio Ltd.
| Country | Israel |
| IPO Date | Jun 27, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 21 |
| CEO | Miranda J. Toledano |
Contact Details
Kiryat Hadassah Minrav Building Jerusalem,
JM 9112002 Israel
Stock Details
| Ticker Symbol | ENTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001638097 |
| CUSIP Number | M40527109 |
| ISIN Number | IL0011429839 |
| SIC Code | 2836 |
Add to Watchlist
Select watchlists to add or remove ENTX